{
    "nct_id": "NCT02072811",
    "official_title": "Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Adult acute myeloid leukemia\n* Age: ≥18 and ≤ 60\n* Clinical condition of the patient allows to carry out induction therapy: ECOG performance status: ≤ 2 and the Hematopoietic Cell Transplant-Co-morbidity Index (HCT-I): ≤3\n* Informed consent to participate in the study (ICF signed)\n* The second early induction start criteria is in addition to the listed above, the percentage of the blasts on the level \\>10% on 7th day.\n\nExclusion Criteria:\n\n* No informed consent for participation in the study, mental illness, which don't allow to obtain informed consent and conduct the treatment according to the protocol\n* Pregnancy\n* HIV infection\n* Active cancer\n* Active hepatitis virus infection\n\nsex: ALL\n\nminimumAge: 18 Years\n\nmaximumAge: 60 Years\n\nstdAges: ['ADULT']",
        "inclusion": "* Adult acute myeloid leukemia\n* Age: ≥18 and ≤ 60\n* Clinical condition of the patient allows to carry out induction therapy: ECOG performance status: ≤ 2 and the Hematopoietic Cell Transplant-Co-morbidity Index (HCT-I): ≤3\n* Informed consent to participate in the study (ICF signed)\n* The second early induction start criteria is in addition to the listed above, the percentage of the blasts on the level >10% on 7th day.",
        "exclusion": "* No informed consent for participation in the study, mental illness, which don't allow to obtain informed consent and conduct the treatment according to the protocol\n* Pregnancy\n* HIV infection\n* Active cancer\n* Active hepatitis virus infection"
    }
}